Todas as matérias desta categoria, das mais recentes às mais antigas.
OrthoPediatrics (NASDAQ:KIDS) announced the full commercial launch of its 3P Pediatric Plating Platform Hip System in the United States after a limited launch phase that included more than 350 surgical implantations.
BioCryst (NASDAQ:BCRX) announced that Japan’s Ministry of Health, Labor and Welfare approved once-daily ORLADEYO (berotralstat) as a preventive treatment for pediatric hereditary angioedema (HAE) patients aged 2 to under 12 years.
Sagimet Biosciences (NASDAQ:SGMT) reported progress on its AURORA U.S. Phase 3 clinical trial evaluating denifanstat, a FASN inhibitor being developed for moderate to severe acne.
Lisa Shalett, CIO at Morgan Stanley Wealth Management, discusses the US Treasury's move to increase the purchases of long-dated bonds and sees a reckoning for stocks "around at least multiples, valuation multiples, is coming, if, in fact, this 10-year pushes forcefully through 4.75 on its way to 5%." (Corrects spelling of guest's name in headline.)
Beyond Air (NASDAQ:XAIR) entered a definitive agreement for UNIVO Pharmaceutical Industries to acquire control of NeuroNOS Israel, a neurology-focused biopharmaceutical company in which Beyond Air owns approximately 58% of fully diluted shares.
The Bank of Nova Scotia (NYSE:BNS) reported fiscal third-quarter 2026 net income of C$2.95 billion, up from C$2.53 billion a year earlier, with higher revenue and earnings growth across business segments.
Lotus Technology (NASDAQ:LOT) completed the acquisition of 100% of the equity interests in Lotus Advance Technologies Sdn Bhd, known as Lotus UK, bringing its British sports car operations and engineering capabilities under a single corporate structure.
McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion, adding clinical research and biopharma commercialization services to its oncology and multispecialty operations.
Kit Juckes, chief FX strategist at Societe Generale, says the US Treasury's move to increase the purchases of long-dated bonds is "management of the market, rather than yet, something that you might call intervention of the bond market." He speaks on "Bloomberg Surveillance."
The Marzetti Company (NASDAQ:MZTI) reported fiscal fourth-quarter 2026 net sales of $465 million, down 2.2% year over year, while adjusted diluted EPS increased 9% to $1.46.
Summit Therapeutics (NASDAQ:SMMT) announced publication of primary analysis results from the Phase III HARMONi clinical trial, showing ivonescimab combined with chemotherapy improved progression-free survival in patients with EGFR-mutated advanced non-small cell lung cancer.
Kanzhun (NASDAQ:BZ) reported second-quarter 2026 revenue of RMB2,398.6 million, up 14.1% year over year, driven by higher online recruitment revenue and growth in enterprise customers and users.
